Compare iShares MSCI Indonesia ETF (EIDO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Indonesia ETF trades at $11.83 (market cap $398.15M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 12.6× iShares MSCI Indonesia ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EIDO | TVTX | |
|---|---|---|
Market Cap | $398.15M | $5.02B |
Volume | 3,087,911 | 2,060,842 |
52-Week High | $19.22 | $67.52 |
52-Week Low | $10.80 | $26.79 |
Typical Hold Time | 76 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.71, up 0.34% with bearish technical signals from moving averages and neutral oscillators. The ETF faces weak price action despite trading at a bargain valuation of 8.7x P/E. Recent news highlights foreign capital rotation away from Asian equities and Indonesia's limited benefit from commodity gains, with 44% financials weighting constraining growth potential.
Outlook remains cautious due to technical downtrend and sector concentration risks. The low valuation offers potential value, but persistent weak momentum and limited EPS growth of 5.9% temper upside. Key risks include dependence on financial sector performance and broader Asian market sentiment shifts.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
